Based on the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) recommendations, the minimum chronic acceptable success rate (objective effectiveness endpoint for a clinical trial) for persAF at the 12-month follow-up is 40% [9] .Although consensus is lacking regarding the preferred treatment strategy for persAF, improving the safety and quality of lesions